Cell & Gene Therapy Insights, 2021
Achieving the full potential of gene therapy requires an optimal balance between safety, efficacy, and manufacturability. At NIMVEC, we develop advanced replication-defective SV40 vector technologies designed to enable efficient gene delivery while minimizing immunogenicity. Combined with a scalable, high-yield manufacturing platform, our approach supports the development of next-generation gene therapies with the potential to improve both clinical performance and patient accessibility.
